Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report by Zhao, Zichen, MD, Su, Chao, PhD, Xiu, Weigang, MD, Wang, Weiya, MD, Zeng, Shasha, MD, Huang, Meijuan, MD, Gong, Youling, MD, Lu, You, MD, PhD, Zhang, Yan, MD, PhD

Get full text

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE... by Zhou, Qing, Prof, Chen, Ming, Prof, Jiang, Ou, Prof, Pan, Yi, Prof, Hu, Desheng, Prof, Lin, Qin, PhD, Wu, Gang, Prof, Cui, Jiuwei, Prof, Chang, Jianhua, Prof, Cheng, Yufeng, Prof, Huang, Cheng, Prof, Liu, Anwen, Prof, Yang, Nong, Prof, Gong, Youling, Prof, Zhu, Chuan, Prof, Ma, Zhiyong, Prof, Fang, Jian, Prof, Chen, Gongyan, Prof, Zhao, Jun, MD, Shi, Anhui, MD, Lin, Yingcheng, Prof, Li, Guanghui, MD, Liu, Yunpeng, Prof, Wang, Dong, Prof, Wu, Rong, Prof, Xu, Xinhua, Prof, Shi, Jianhua, Prof, Liu, Zhihua, MD, Cui, Na, PhD, Wang, Jingru, PhD, Wang, Qiang, MM, Zhang, Ran, MSc, Yang, Jason, MD, Wu, Yi-Long, Prof

Get full text

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, plac... by Wang, Jie, Prof, Zhou, Caicun, Prof, Yao, Wenxiu, Prof, Wang, Qiming, Prof, Min, Xuhong, BS, Chen, Gongyan, Prof, Xu, Xingxiang, Prof, Li, Xingya, Prof, Xu, Fei, Prof, Fang, Yong, Prof, Yang, Runxiang, Prof, Yu, Guohua, Prof, Gong, Youling, Prof, Zhao, Jun, Prof, Fan, Yun, Prof, Liu, Quan, Prof, Cao, Lejie, Prof, Yao, Yu, Prof, Liu, Yunpeng, Prof, Li, Xiaoling, Prof, Wu, Jingxun, Prof, He, Zhiyong, Prof, Lu, Kaihua, Prof, Jiang, Liyan, Prof, Hu, Chengping, Prof, Zhao, Wenhua, MD, Zhang, Ben, Ms, Shi, Wei, MD, Zhang, Xiaojing, MD, Cheng, Ying, Prof

Get full text